Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients
Executive Summary
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.